These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20831047)

  • 21. Warfarin and pharmacogenomic testing: what would Pascal do?
    Teagarden JR
    Pharmacotherapy; 2009 Mar; 29(3):245-7. PubMed ID: 19249943
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacogenetic-based dosing of warfarin.
    Med Lett Drugs Ther; 2008 May; 50(1286):39-40. PubMed ID: 18487958
    [No Abstract]   [Full Text] [Related]  

  • 23. The long and winding road to warfarin pharmacogenetic testing.
    Ginsburg GS; Voora D
    J Am Coll Cardiol; 2010 Jun; 55(25):2813-5. PubMed ID: 20579536
    [No Abstract]   [Full Text] [Related]  

  • 24. Role of warfarin pharmacogenetic testing in clinical practice.
    Tan GM; Wu E; Lam YY; Yan BP
    Pharmacogenomics; 2010 Mar; 11(3):439-48. PubMed ID: 20402581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).
    Anderson JL; Horne BD; Stevens SM; Woller SC; Samuelson KM; Mansfield JW; Robinson M; Barton S; Brunisholz K; Mower CP; Huntinghouse JA; Rollo JS; Siler D; Bair TL; Knight S; Muhlestein JB; Carlquist JF
    Circulation; 2012 Apr; 125(16):1997-2005. PubMed ID: 22431865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.
    Patrick AR; Avorn J; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):429-36. PubMed ID: 20031873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
    Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
    Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Application of warfarin pharmacogenetics].
    Tomek A; Mat'oska V; Kumstýrfová T; Táborský L
    Vnitr Lek; 2009 Jun; 55(6):565-9. PubMed ID: 19662888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Impact of pharmacogenetic testing on the risk of bleedings and excessive hypocoagulation episodes in the use of warfarin: the first meta-analysis of Russian prospective studies].
    Sychev DA; Ivashchenko DV; Rusin IV
    Ter Arkh; 2014; 86(4):64-71. PubMed ID: 24864470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin].
    Kondrat'eva LV; Patrusheva NL; Patrushev LI; Aleksandrova EN; Kovalenko TF; Ostriakova EV; Reshetniak TM
    Ter Arkh; 2010; 82(5):33-9. PubMed ID: 20597268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pharmacogenetic versus a clinical algorithm for warfarin dosing.
    Kimmel SE; French B; Kasner SE; Johnson JA; Anderson JL; Gage BF; Rosenberg YD; Eby CS; Madigan RA; McBane RB; Abdel-Rahman SZ; Stevens SM; Yale S; Mohler ER; Fang MC; Shah V; Horenstein RB; Limdi NA; Muldowney JA; Gujral J; Delafontaine P; Desnick RJ; Ortel TL; Billett HH; Pendleton RC; Geller NL; Halperin JL; Goldhaber SZ; Caldwell MD; Califf RM; Ellenberg JH;
    N Engl J Med; 2013 Dec; 369(24):2283-93. PubMed ID: 24251361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
    Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
    Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of warfarin dose by population-specific pharmacogenomic algorithm.
    Pavani A; Naushad SM; Rupasree Y; Kumar TR; Malempati AR; Pinjala RK; Mishra RC; Kutala VK
    Pharmacogenomics J; 2012 Aug; 12(4):306-11. PubMed ID: 21358752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Warfarin resistance and related pharmacogenetic information].
    Takahashi H
    Brain Nerve; 2008 Nov; 60(11):1365-71. PubMed ID: 19069171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
    El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
    Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population.
    Pavani A; Naushad SM; Mishra RC; Malempati AR; Pinjala R; Kumar TR; Kutala VK
    Pharmacogenomics; 2012 Jun; 13(8):869-78. PubMed ID: 22676192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
    Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
    Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.